INCY vs CRL stock comparison
Incyte vs. Charles River Laboratories International · data as of November 13, 2026
Incyte (INCY) has a market value of about $24.7B, Charles River Laboratories International (CRL) about $16.2B. Over their latest twelve months Incyte had revenue of $6.0B and Charles River Laboratories International $4.0B.
On our five checks Incyte scores higher: 2.8 out of 5 (average) against 1.2 (weak).
By area, the stronger company is Incyte on future growth; Incyte on track record; Incyte on financial health; Charles River Laboratories International on shareholder returns.
Incyte is cheaper on earnings (P/E 61.7 vs. 367.4).
Incyte leads on 16 of the compared lines and Charles River Laboratories International on 3.
Side by side
| INCY | CRL | |
|---|---|---|
| Size and price | ||
| Market cap | $24.7B | $16.2B |
| Share price | $120.97 | $337.97 |
| Score | ||
| Overall score (of 5) | 2.8 | 1.2 |
| Value | 0 | 0 |
| Future growth | 4 | 1 |
| Track record | 3 | 0 |
| Financial health | 5 | 2 |
| Shareholder returns | 2 | 3 |
| Valuation | ||
| P/E (TTM) | 61.7 | 367.4 |
| Forward P/E | 15.1 | 26.7 |
| Price / free cash flow | 36.3 | 40.5 |
| Price / sales | 4.1 | 4.1 |
| EV / EBITDA | 29.5 | 42.4 |
| PEG | — | — |
| DCF value vs. price | −48% | −76% |
| Business | ||
| Revenue | $6.0B | $4.0B |
| Net income | $403M | $40M |
| Free cash flow | $680M | $400M |
| Net margin | 6.7% | 1.0% |
| Gross margin (5-yr avg.) | 93.5% | — |
| ROIC (5-yr avg.) | 10.6% | 5.6% |
| Growth | ||
| Revenue growth (1 yr) | 21.2% | -0.9% |
| Revenue growth (5 yrs, per year) | 14.0% | 6.6% |
| EPS growth (5 yrs, per year) | — | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | — | -$2.7B |
| Dividend yield | None | None |
| Shareholder yield | 0.0% | 2.2% |
| Analysts | ||
| Upside to average target | +9% | +4% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: INCY TTM to September 30, 2026, CRL TTM to September 26, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Incyte or Charles River Laboratories International?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Incyte scores 2.8 out of 5 and Charles River Laboratories International 1.2; the table shows where each one is stronger.
Is Incyte cheaper than Charles River Laboratories International?
On trailing earnings, Incyte trades at a P/E of 61.7 and Charles River Laboratories International at 367.4, so Incyte is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Incyte or Charles River Laboratories International?
Over five years Incyte grew revenue about 14.0% a year and Charles River Laboratories International about 6.6% a year.
Full Incyte analysis → Full Charles River Laboratories International analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.